Skip to main content

Table 1 Patient and tumour characteristics

From: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Characteristic No. of Patients
(n = 39)
%
Age (years)
Median 63
Range 38-80
Gender
Male 30 77
Female 9 23
ECOG performance status
0 16 41
1 17 44
2 6 15
Disease status
Locally advanced 0 0
Metastatic 39 100
Site of the primary tumour
Oesophago-gastric junction 22 56
Stomach 17 44
Histological classification (Laurén)
Intestinal 22 56
Non-intestinal (diffuse or mixed) 17 44
  1. Abbreviation: ECOG Eastern Cooperative Oncology Group